secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001171843-25-004474
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial
--------------------------------------------------------------------------------

- Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.
- Funds directed to ongoing TUSCANY Phase 1/2 study of tuspetinib triplet therapy in newly diagnosed AML.
- Tuspetinib combination with venetoclax/azacitidine showed safety and MRD negativity in early data.
- Loan facility announced June 20, 2025; proceeds extend Aptose's cash runway for clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/0001171843-25-004474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/f8k_071525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer